AbbVie Inc. Derivative Liability, Fair Value, Gross Liability
AbbVie Inc. (ABBV) had Derivative Liability, Fair Value, Gross Liability of $284.00 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Offsetting
us-gaap:DerivativeFairValueOfDerivativeLiability · last filed 2026-08-03
- 2026-06-30: Derivative Liability, Fair Value, Gross Liability $284.00M.
- 2026-03-31: Derivative Liability, Fair Value, Gross Liability $338.00M.
- 2025-12-31: Derivative Liability, Fair Value, Gross Liability $540.00M.
- 2025-09-30: Derivative Liability, Fair Value, Gross Liability $690.00M.
| Period end | Derivative Liability, Fair Value, Gross Liability |
|---|---|
| 2026-06-30 | $284.00M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $338.00M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $540.00M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $690.00M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $880.00M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $252.00M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $266.00M 10-K · filed 2026-02-20 |
| 2024-09-30 | $446.00M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $341.00M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $428.00M 10-Q · filed 2024-05-03 |
| 2023-12-31 | $496.00M 10-K · filed 2025-02-14 |
| 2023-09-30 | $531.00M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $542.00M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $544.00M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $524.00M 10-K · filed 2024-02-20 |
| 2022-09-30 | $509.00M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $318.00M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $213.00M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $37.00M 10-K · filed 2023-02-17 |
| 2021-09-30 | $49.00M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $100.00M 10-Q · filed 2021-08-02 |
| 2021-03-31 | $126.00M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $166.00M 10-K · filed 2022-02-18 |
| 2020-09-30 | $110.00M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $77.00M 10-Q · filed 2020-08-04 |
| 2020-03-31 | $57.00M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $132.00M 10-K · filed 2021-02-19 |
| 2019-09-30 | $139.00M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $164.00M 10-Q · filed 2019-08-05 |
| 2019-03-31 | $401.00M 10-Q · filed 2019-05-03 |
| 2018-12-31 | $492.00M 10-K · filed 2020-02-21 |
| 2018-09-30 | $723.00M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $684.00M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $712.00M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $550.00M 10-K · filed 2019-02-27 |
| 2017-09-30 | $498.00M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $444.00M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $420.00M 10-Q · filed 2017-05-05 |
| 2016-12-31 | $376.00M 10-K · filed 2018-02-16 |
| 2016-09-30 | $32.00M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $55.00M 10-Q · filed 2016-08-05 |
| 2016-03-31 | $109.00M 10-Q · filed 2016-05-06 |
| 2015-12-31 | $102.00M 10-K · filed 2017-02-17 |
| 2015-09-30 | $23.00M 10-Q · filed 2015-11-06 |
| 2015-06-30 | $208.00M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $93.00M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $243.00M 10-K · filed 2016-02-19 |
| 2014-09-30 | $508.00M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $298.00M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $417.00M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $505.00M 10-K · filed 2015-02-20 |
| 2013-09-30 | $432.00M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $437.00M 10-Q · filed 2013-08-09 |
| 2013-03-31 | $143.00M 10-Q · filed 2013-05-08 |
| 2012-12-31 | $106.00M 10-K · filed 2014-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |